<PAGE>
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
March 26, 1997
------------------------------
Date of Report
(Date of earliest event reported)
ELECTROPHARMACOLOGY, INC.
-------------------------
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-25828 95-4315412
- --------------------------------- ------------------------ -------------------
(State or other Jurisdiction of (Commission File Number) (I.R.S. Employer
Incorporation) Identification No.)
2301 N.W. 33RD COURT, SUITE 102
POMPANO BEACH, FLORIDA 33069
- --------------------------------- --------------
(Address of Principal Executive (Zip Code)
Offices)
(954) 975-9818
----------------------------------------------------
(Registrant's telephone number, including area code)
================================================================================
<PAGE>
ITEM 5. OTHER EVENTS.
Electropharmacology, Inc. (the "Registrant") announced on March 26, 1997 the
resignation of Don Soldatis, the Registrant's Chief Financial Officer, effective
immediately. The resignation did not result from any disagreements over
accounting principles or practices or financial statement disclosure. The
Registrant also stated that it was filing a Form 12b-25 to notify the Securities
and Exchange Commission that, as a result of the resignation, the Registrant
would not file its 1996 Form 10-KSB until April 15, 1997.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Electropharmacology, Inc.
By: /s/ Joseph Mooibroek
---------------------------------------
Joseph Mooibroek
President and Chief Executive Officer
March 26, 1997
2
